HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Monday reported a loss of $26.9 million in its second quarter.
The Houston-based company said it had a loss of 58 cents per share.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 54 cents per share.
The drug developer posted revenue of $1.4 million in the period, beating Street forecasts. Three analysts surveyed by Zacks expected $233,000.
In the final minutes of trading on Monday, the company's shares hit $1.30. A year ago, they were trading at $5.87.